Nomura has maintained its purchase rating on CG powerbott, causing the target price to be Rs 825 before Rs 900. Analysts said that when the company invited the estimates of analysts, its railway business dropped its gap down. They feel that the demand for tailwind for the power system remains intact.However, the company is receiving market share in value -added industrial system products.Citragroup maintained its sales rating on PNB with a target price at Rs 91. Analysts stated that the lender violated 1% returns at the property rate, while its quarterly profit was assisted by Treasury profit, recovery. He also stated that PNB’s net interest slipped during the quarter and slippery was high. Credit growth guidance for FY26 is 11–12% and deposited at 9–10%.CITI maintained its purchase rating on HPCL, with the target price increased from Rs 510 to Rs 460. Analysts raised FY26/27 Ebitda estimates by 10%/5%for HPCL. The company has changed its marketing and refining margin estimates. Analysts said that the opposite LPG from the government may come from compensation for the target price.Motelle Oswal Financial Services has upgraded Arobindo Pharma to buy for Rs 1,360 with a target price. Analysts feel that the company’s showcase is diversified and supported by the capacity. It is actively investing in many high-affected segments to run continuous growth over the next 3-5 years. The company stands out to be the most diverse American generic portfolio, demonstrating flexibility against pricing pressure. Additionally, it is invested in differentiated abilities and the company is well positioned for constant speed in the event of facilities for regulated markets.Elara Securities India has updated Larsen and Toubro to deposit a rating with a target price of Rs 4,051. Analysts feel that L&T international projects remain its major driver. Its main occupation is stronger and running investment in new-age businesses, such as semiconductors and data centers, can add new avenues for development.Disclaimer: The opinion, analysis and recommendations expressed here are of brokerage and do not reflect the views of the Times of India. Always consult a qualified investment advisor or financial planner before taking any investment decision.
